Bookmarks
Characterisation of COVID-19 outcomes in a high-risk cohort: Assessment of background levels of autoantibodies as a prognostic marker for severe COVID-19 infection.
Safe People
University of Dundee
Academic Institute
Frank Sullivan
Safe Projects
eDRIS-2021-0124
Patients with more severe forms of SARS-CoV-2 exhibit activation of immunological cascades. Participants (current or ex-smokers with at least 20 years pack history) in a trial (Early Diagnosis of Lung Cancer, Scotland [ECLS]) of autoantibody detection to predict lung cancer risk had seven autoantibodies measured 5 years before the pandemic. This study compared the response to Covid infection in study participants who tested positive and negative to antibodies to tumour-associated antigens: p53, NY-ESO-1, CAGE, GBU4-5, HuD, MAGE A4 and SOX2.
09/10/2020
Safe Data
SICSAG (Scottish Intensive Care Society Audit Group)
2 Datasets Supplied by the Researcher
Scottish Cancer Registry (SMR06)
Safe Setting
Release